Hunt for SARS source far from over: researcher
02 September, 2003 by Graeme O'NeillVirologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified.
Qld's Élan joins with US Meditech on biohazard
01 September, 2003 by Melissa TrudingerQueensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax.
New virus linked to breast cancer
22 August, 2003 by Jeremy TorrResearchers at the Prince of Wales Hospital have established a link between breast cancer and the human form of a mouse virus.
Novogen scores new US patent
19 August, 2003 by Jeremy TorrBiopharma Novogen has been granted a US patent for isoflavone treatment for fibroids and endometriosis specific to women.
Victor Chang Institute to work with BioDiem
19 August, 2003 by Jeremy TorrSydney's Victor Chang Cardiac Research Institute has signed a deal to investigate a tissue restorative agent, BDM-K, for Melbourne biopharma BioDiem
Watch for new wave of mad cow: Masters
15 August, 2003 by Melissa TrudingerWhile the incidence of variant Creutzfeldt-Jakob disease (vCJD) -- the human form of mad cow disease -- appears to have slowed in the UK after 146 confirmed cases since the epidemic began in the mid-1990's, a new wave of cases could be waiting in the wings, according to Australian neuroscientist Prof Colin Masters.
AustCancer shuffles staff and direction
14 August, 2003 by Jeremy TorrAustralian Cancer Technology (AustCancer) has changed tack with new management, a new product line and a move from Perth to Sydney -- all in one day.
Neuro facility teams with UK firm to develop MND model
12 August, 2003 by Melissa TrudingerA commercial alliance has been formed between the National Neuroscience Facility (NNF) and UK company Danio Labs, to develop a zebrafish model for Motor Neurone Disease (MND) and other neurodegenerative diseases.
Cytopia to use Start grant in pulmonary disorder work
06 August, 2003 by Graeme O'NeillMelbourne biomedical company Cytopia has won a $1.7 million AusIndustry Start grant to develop treatments for chronic obstructive pulmonary disorder (COPD), a currently untreatable condition that affects more than 600 million people worldwide.
Metabolic to spend $2.1m grant on clinical trials
06 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) has been granted an R&D Start grant of up to AUD$2.1 million to conduct its Phase IIb clinical trial for its obesity drug AOD9604.
WEHI's Vaux wins Victoria Prize
05 August, 2003 by Melissa TrudingerWalter and Eliza Hall Institute cancer researcher Dr David Vaux has been awarded the 2003 Victoria Prize for his pioneering work on the how, when and why of cell death.
Melbourne Uni student wins prestige award
31 July, 2003 by Jeremy TorrThe Swiss-based Serono Foundation has awarded a US$90,000 postgraduate fellowship grant to an ex-Melbourne Uni PhD to pursue research into cancer biology.
Qld start-up Thrombostat raises $800,000 in VC, grants
24 July, 2003 by Pete YoungBrisbane start-up company Thrombostat has attracted AUD$800,000 in venture capital and grants to develop drugs that could displace aspirin in long-term prevention and treatment of cardiovascular disease.
US backs down on health IP
22 July, 2003 by Jeremy TorrStrong negative reaction from local industry bodies has led to the US modifying plans to snare biotech IP by funding grants to Australian researchers.
Meditech starts anti-cancer clinical trial
15 July, 2003 by Jeremy TorrMeditech Research is to start clinical trials on its HyCAMP anti-cancer compound, targeting colorectal tumours in patients at the Centre for the Development of Cancer Therapeutics in Melbourne.
